-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AG-73305 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AG-73305 in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AG-73305 in Diabetic Macular Edema Drug Details: AG-73305 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Endometrial Cancer Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewRetinal Vascular Occlusion – Drugs In Development, 2024
Empower your strategies with our Retinal Vascular Occlusion – Drugs In Development, 2024 report and make more profitable business decisions. Retinal vascular occlusion is a condition that affects the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. It occurs when a blood vessel is blocked by a clot or compressed by another vessel, preventing blood from reaching or leaving the retina. This can cause vision loss or blindness in the affected eye. There...
-
Product Insights
NewRetinal Vein Occlusion – Drugs In Development, 2024
Empower your strategies with our Retinal Vein Occlusion – Drugs In Development, 2024 report and make more profitable business decisions. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion drugs in...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Triple-Negative Breast Cancer (TNBC) Drug Details: XTX-301 is under development for treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AG-73305 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AG-73305 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AG-73305 in Diabetic Macular Edema Drug Details:AG-73305 is under development for the...